Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

AstraZeneca to Pay Soriot $1.76 Million in Base Salary

AstraZeneca Plc said it will pay Chief Executive Officer Pascal Soriot 1.1 million pounds ($1.76 million) a year in base salary, more than larger U.K. rival GlaxoSmithKline Plc gave its CEO last year.

Soriot, who began his tenure as CEO on Oct. 1, may also be awarded 69,108 shares at 2,894 pence each, subject to a four-year performance period and a subsequent four-year holding period, the company said in a statement today. His bonus target for the year is 100 percent of his salary, AstraZeneca said.

Soriot joined the London-based drugmaker as it searches for licensing deals, partnerships and acquisitions of late-stage assets to replenish the pipeline and boost sales. He suspended the company’s share buyback program on his first day on the job as AstraZeneca reviews its strategy.

Glaxo, the U.K.’s biggest drugmaker, paid CEO Andrew Witty a base salary of 1 million pounds last year.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.